Loading organizations...

§ Private Profile · Seattle, WA, USA
Magnolia Medical Technologies is a technology company.
Magnolia Medical Technologies has raised $79.8M across 3 funding rounds.
Key people at Magnolia Medical Technologies.
Magnolia Medical Technologies has raised $79.8M in total across 3 funding rounds.
Magnolia Medical Technologies provides Steripath, an FDA 510(k)-cleared device for accurate sepsis diagnostics by reducing blood culture contamination. It actively diverts and sequesters the initial blood aliquot, containing skin contaminants, into a chamber. A separate pathway then collects clean samples for culture, ensuring integrity. This technology addresses a critical challenge in clinical practice, improving the reliability of diagnostic results.
The company originates from Dr. Richard Patton, former Chief of Pathology at UW Medicine. Dr. Patton conceived the Initial Specimen Diversion Technique, conducting a pivotal 2006 study published in 2010. His research highlighted the need for improved diagnostic accuracy, addressing contamination causing misdiagnosis and inappropriate antibiotic usage, which became the foundational insight for Magnolia Medical Technologies.
Healthcare institutions utilize Steripath to enhance sepsis diagnosis. Magnolia Medical Technologies pursues a "Mission to ZERO," aiming to eliminate in-vitro diagnostic errors through accurate, timely testing. The company envisions precise diagnostics leading to better patient outcomes, reduced costs, and a stronger fight against antibiotic resistance.
Magnolia Medical Technologies is a Seattle-based medical device company that builds the Steripath® Initial Specimen Diversion Device (ISDD®) family to reduce blood culture contamination and improve sepsis diagnostic accuracy for hospitals and health systems[1][3]. The company commercializes evidence-backed collection devices and services that aim to cut false‑positive blood culture results, lower unnecessary antibiotic use and related costs, and support diagnostic stewardship across acute care settings[1][4].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Healthcare Landscape
Quick Take & Future Outlook
Quick take: Magnolia Medical has converted a clinician‑identified problem into a patented, FDA‑cleared device family and a data service that together address a measurable source of diagnostic error—its trajectory depends on scaling measurable clinical and economic impact and translating that into sustained, system‑level adoption[1][3][4][5].
Key people at Magnolia Medical Technologies.
Magnolia Medical Technologies has raised $79.8M in total across 3 funding rounds.
Magnolia Medical Technologies's investors include Ovid Amadi, Marc-Andre Marcotte, CFA, Canepa Advanced Healthcare Fund, HealthQuest Capital, Janus Henderson Investors, Sightline Partners, RTW Investments, Garheng Kong.
Magnolia Medical Technologies has raised $79.8M across 3 funding rounds. Most recently, it raised $46.0M Other Equity in February 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 22, 2022 | $46M Venture Round | Ovid Amadi, Marc Andre Marcotte, CFA | Canepa Advanced Healthcare Fund, HealthQuest Capital, Janus Henderson Investors, SightLine Partners | Announced |
| Jan 1, 2019 | $20M Series C | RTW Investments | Canepa Advanced Healthcare Fund, HealthQuest Capital, SightLine Partners | Announced |
| Jul 14, 2016 | $13.8M Series B | Garheng Kong | — | Announced |